September 27, 2017 | Featured
Finch Therapeutics and OpenBiome have developed an orally administered microbial therapy for recurrent C. difficile infection.
FIN-403 harnesses the power of Phloral® to target delivery of healthy microbiota to the site of infection in the colon. FIN-403 demonstrated 88% per-protocol efficacy in an initial dose-finding study with 26 patients. DNA sequencing also showed successful and stable engraftment of the full diversity of the healthy microflora.
Copyright © 2018 Intract Pharma
Website Design by Creative Brand Design